Road2HardCoreIron

Tofisopam is generally being accepted as a replacement for Etizolam.

Tofisopam is an atypical benzodiazepine tranquilliser drug. It is currently used in Russia, Japan, and several European countries to treat various psychiatric conditions (mainly anxiety disorders). Several studies also suggests that Tofisopam does have antipsychotic effect.

One of the biggest advantages of Tofisopam over conventional benzodiazepines is that it does not cause sedation and is not addictive, because of the structural differences.

Tofisopam has unique chemical structure, which determines its pharmacological effects that are differs from that of other benzodiazepine tranquillisers. Tofisopam is not a GABA receptors agonist does not binds to benzodiazepine receptors.

It is suggested that a possible target of action of 2,3-benzodiazepines is the opioid signal transduction. This suggestion is consistent with the results of animal studies, which shown that 2,3-BZDs potentiate the effects of opioid agonists, and their behavioural effects were inhibited by induced state of opioid tolerance.

Besides having anxiolytic action, Tofisopam has mild stimulating effect. Studies suggest that Tofisopam increase the sensitivity of central dopamine receptors, as it is shown to potentiate the effects of dopaminergic stimulants.